Evidence map›Paper›PMID 37833450›Full record

ArticleBreast cancer research and treatment2024

The impact of histologic subtype on primary site surgery in the management of metastatic lobular versus ductal breast cancer: a population based study from the National Cancer Database (NCDB).

Harriet T Rothschild, Elle N Clelland, Mary Kathryn Abel, A Jo Chien, Amy M Shui, Laura Esserman, Seema A Khan, Rita A Mukhtar

Open access · hybridAbstract read
In one paragraph

Article in Breast cancer research and treatment, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Harriet T RothschildUniversity of California, San Francisco School of Medicine, 533 Parnassus Avenue, San Francisco, CA, 94143, USA.ORCID http://orcid.org/0000-0001-5311-2872
Elle N ClellandUniversity of California, San Francisco School of Medicine, 533 Parnassus Avenue, San Francisco, CA, 94143, USA.ORCID http://orcid.org/0000-0003-1439-0532
Mary Kathryn AbelUniversity of California, San Francisco School of Medicine, 533 Parnassus Avenue, San Francisco, CA, 94143, USA.ORCID http://orcid.org/0000-0003-0447-5823
A Jo ChienDepartment of Medicine, University of California, San Francisco, 1825 4th St, San Francisco, CA, 94158, USA.ORCID http://orcid.org/0000-0003-2978-6249
Amy M ShuiDepartment of Epidemiology & Biostatistics, University of California, San Francisco, 550 16th Street, San Francisco, CA, 94158, USA.
Laura EssermanDepartment of Surgery, University of California, San Francisco, 400 Parnassus Avenue, 1825 4th Street, 3rd Floor, Box 1710, San Francisco, CA, 94143, USA.ORCID http://orcid.org/0000-0001-9202-4568
Seema A KhanDepartment of Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL, 60611, USA.ORCID http://orcid.org/0000-0002-6307-2023
Rita A MukhtarDepartment of Surgery, University of California, San Francisco, 400 Parnassus Avenue, 1825 4th Street, 3rd Floor, Box 1710, San Francisco, CA, 94143, USA. rita.mukhtar@ucsf.edu.ORCID http://orcid.org/0000-0001-8079-7846
University of California, San Francisco · USNorthwestern University · US

Funding

NRSA Training CoreTL1TR001871 · NCATS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KANAYA, ALKA M., SOMSOUK, MA · 2016 to 2025
$10.1M
Identifying responders to chemotherapy in invasive lobular carcinoma of the breast: development of a multivariable clinical prediction toolK08CA256047 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MUKHTAR, RITA · 2021 to 2025
$1.3M
NCATS NIH HHS TL1 TR 001871NCATS NIH HHS TL1 TR001871NCI NIH HHS K08 CA256047NCI NIH HHS K08CA256047
6 · The paper itself

Abstract

purposePrimary site surgery for metastatic breast cancer improves local control but does not impact overall survival. Whether histologic subtype influences patient selection for surgery is unknown. Given differences in surgical management between early-stage lobular versus ductal disease, we evaluated the impact of histology on primary site surgery in patients with metastatic breast cancer.

methodsThe National Cancer Database (NCDB, 2010-2016) was queried for patients with stage IV HR-positive, HER2-negative invasive lobular carcinoma (ILC) and invasive ductal carcinoma (IDC). We compared clinicopathologic features, primary site surgery rates, and outcomes by histologic subtype. Multivariable Cox proportional hazard models with and without propensity score matching were used for overall survival (OS) analyses.

resultsIn 25,294 patients, primary site surgery was slightly but significantly less common in the 6,123 patients with ILC compared to the 19,171 patients with IDC (26.9% versus 28.8%, p = 0.004). Those with ILC were less likely to receive chemotherapy (41.3% versus 47.4%, p < 0.0001) or radiotherapy (29.1% versus 37.9%, p < 0.0001), and had shorter OS. While mastectomy rates were similar, those with ILC who underwent lumpectomy had significantly higher positive margin rates (ILC 15.7% versus IDC 11.2%, p = 0.025). In both groups, the odds of undergoing surgery decreased over time, and were higher in younger patients with T2/T3 tumors and higher nodal burden.

conclusionLobular histology is associated with less primary site surgery, higher positive margin rates, less radiotherapy and chemotherapy, and shorter OS compared to those with HR-positive HER2-negative IDC. These findings support the need for ILC-specific data and treatment approaches in the setting of metastatic disease.

Indexed as

Breast NeoplasmsCarcinoma, Ductal, BreastCarcinoma, LobularFemaleHumansMastectomyMastectomy, SegmentalLobularMetastaticNCDBSurgery

Identifiers

PMID37833450
PMCPMC10787876
OpenAlexW4387614236

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.